Valuation: ADC Therapeutics SA

Market Cap 183M 167M 153M 140M 262M 16.93B 275M 1.87B 742M 9.25B 686M 672M 29.03B P/E 2026 *
-1.86x
P/E 2027 * -2.02x
Enterprise Value 183M 167M 153M 140M 262M 16.93B 275M 1.87B 742M 9.25B 686M 672M 29.03B EV / Sales 2026 *
2.1x
EV / Sales 2027 * 1.8x
Free-Float
85.5%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: ADC Therapeutics SA

1 day-0.38%
1 week-3.36%
Current month-15.36%
1 month-14.80%
3 months+34.88%
6 months-60.03%
Current year-63.31%
1 week 1.24
Extreme 1.24
1.42
1 month 1.24
Extreme 1.24
1.86
Current year 0.78
Extreme 0.7796
4.98
1 year 0.78
Extreme 0.7796
4.98
3 years 0.68
Extreme 0.684
6.04
5 years 0.36
Extreme 0.359908
23.28
10 years 0.36
Extreme 0.359908
56.59
Manager TitleAgeSince
Chief Executive Officer 53 09/05/2022
Director of Finance/CFO 54 19/12/2022
Chief Tech/Sci/R&D Officer 52 01/10/2024
Director TitleAgeSince
Director/Board Member 67 01/06/2019
Director/Board Member 53 01/06/2018
Chairman 59 01/03/2020
Date Insider Type Main position Quantity % Market Cap. Importance
30/6/26 Free

Chief Executive Officer

675,000 0.5307%
30/6/26 Free

Chief Financial Officer

203,700 0.1602%
30/6/26 Free

Chief Technology Officer

213,900 0.1682%
Change 5-day change 1-year change 3-year change Capi.($)
-0.38%-3.36%-67.54%+82.32% 183M
-2.49%-6.35%+51.07%+64.95% 65.42B
-0.63%-2.91%+6.20%+89.22% 58.91B
-2.37%-2.22%+22.87%+82.31% 55.24B
-0.92%-5.11%+13.16%+110.38% 45.66B
-0.70%-6.28%+14.45%+21.04% 41.29B
-0.93%+1.67%+20.83%+45.03% 36.82B
+1.50%-6.22%+131.22%+643.56% 34.48B
-0.80%+0.61%+77.26%+56.26% 32.5B
+0.33%+19.97%-27.19%+490.41% 31.69B
Average -0.75%-1.37%+24.23%+168.55% 40B
Weighted average by Cap. -1.00%-1.28%+32.56%+152.15%

Financials

2026 *2027 *
Net sales 87.22M 79.44M 73.2M 66.59M 125M 8.08B 131M 891M 354M 4.41B 327M 320M 13.84B 101M 92.37M 85.12M 77.42M 145M 9.39B 153M 1.04B 412M 5.13B 381M 373M 16.1B
Net income -109M -99.65M -91.82M -83.52M -157M -10.13B -165M -1.12B -444M -5.53B -411M -402M -17.37B -123M -112M -104M -94.17M -177M -11.42B -186M -1.26B -501M -6.24B -463M -453M -19.58B
Net Debt - -
Projected Income Statement - Annual - ADC Therapeutics SA
Logo ADC Therapeutics SA
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Employees
191
Date Price Change Volume
21/11/26 US$1.290 -0.77% 478,640
19/11/26 US$1.300 -5.11% 752,411
18/11/26 US$1.370 +1.48% 1,170,158
17/11/26 US$1.350 +8.00% 1,097,116
16/11/26 US$1.250 -6.72% 1,480,602
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - ADC Therapeutics SA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.300USD
Average target price
3.333USD
Spread / Average Target
+156.41%
  1. Stock Market
  2. Stocks
  3. ADCT Stock